News · 26 weeks420%
2025-12-072026-05-31
Mix490d
- Leadership2(50%)
- Other2(50%)
Latest news
25 items- FDAFDA Approval for BIZENGRI issued to MERUS N.V.Submission status for MERUS N.V.'s drug BIZENGRI (SUPPL-10) with active ingredient ZENOCUTUZUMAB-ZBCO has changed to 'Approval' on 05/08/2026. Application Category: BLA, Application Number: 761352, Application Classification:
- FDAFDA Approval for BIZENGRI issued to MERUS N.V.Submission status for MERUS N.V.'s drug BIZENGRI (SUPPL-10) with active ingredient ZENOCUTUZUMAB-ZBCO has changed to 'Approval' on 05/11/2026. Application Category: BLA, Application Number: 761352, Application Classification:
- PRLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateAdvancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- Leon
- PRLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. to its Board of Directors, effective as of May 5, 2026. The company also announced that John Fluke, Jr., who has served on the Board of Directors since 2014, retired effective May 4, 2026. "We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors," said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. "Collectively, they bring
- PREGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightThe EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
- SECSEC Form 15-12G filed by Merus N.V.15-12G - Merus N.V. (0001651311) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.SCHEDULE 13D/A - Merus N.V. (0001651311) (Subject)
- SECAmendment: SEC Form 25-NSE/A filed by Merus N.V.25-NSE/A - Merus N.V. (0001651311) (Subject)
- SECMerus N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders8-K - Merus N.V. (0001651311) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Merus N.V.SC 14D9/A - Merus N.V. (0001651311) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Merus N.V.SC TO-T/A - Merus N.V. (0001651311) (Subject)
- INSIDERLarge owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)4 - Merus N.V. (0001651311) (Issuer)
- INSIDERLarge owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)4 - Merus N.V. (0001651311) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Merus N.V.SCHEDULE 13D - Merus N.V. (0001651311) (Subject)
- INSIDERLarge owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)4 - Merus N.V. (0001651311) (Issuer)
- PRImmunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ:ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ:AVBP), Merus N.V. (NASDAQ:MRUS), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal ca
- INSIDERSEC Form 4 filed by Chief Financial Officer & PFO Perry Gregory D4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by Director Mehra Anand4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by Director Kanavy Len4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by Director Haddock Jason4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by COO & GC Silverman Peter B.4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Zohren Fabian4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO & PEO Lundberg Sven Ante4 - Merus N.V. (0001651311) (Issuer)
- INSIDERSEC Form 4 filed by Director Pucci Paolo4 - Merus N.V. (0001651311) (Issuer)
- INSIDERVP Controller, PAO Shuman Harry closing all direct ownership in the company (SEC Form 4)4 - Merus N.V. (0001651311) (Issuer)
MRUS FAQ
7 questionsWhat does Merus N.V. do?
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the...Where does MRUS stock trade?
Merus N.V. (MRUS) is listed on NASDAQ.What sector and industry is MRUS in?
Merus N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Merus N.V. go public?
Merus N.V. (MRUS) completed its IPO in 2016.What are analysts saying about MRUS?
Merus N.V. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2025-09-17.What companies are similar to MRUS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MRUS side-by-side with any of them on Quantisnow.How can I track MRUS on Quantisnow?
Quantisnow aggregates Merus N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRUS to receive live email and push alerts on every new disclosure.